NEWS RELEASE

Inovio Announces Leadership Appointments

2017-06-28

PLYMOUTH MEETING, Pa., June 28, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced leadership appointments to support its growth and expanding strategic and operational initiatives. Inovio promoted Dr. Keiko Simon to Vice President, Alliance and Program Management and Jeffrey C. Richardson to Vice President, Strategic Relations.

Dr. Simon, who joined Inovio in 2013, will be responsible for managing the company's relationships with its external partners including product development collaborations with MedImmune, Regeneron, and Genentech, and other collaborations. She also will direct internal project management of Inovio's pipeline programs in development including its phase 3 program. She joined Inovio after a 20-year career at Merck in project and portfolio management, supporting the infectious disease and vaccine therapeutic areas and external partnerships.

Jeffrey C. Richardson joined Inovio in 2012 after serving Amgen and GSK in global communications positions. He will be responsible for directing Inovio's media relations, human resources, government affairs and executive communications efforts.

Dr. J. Joseph Kim, Inovio's President and CEO, said, "This is a transformative time for Inovio. We are moving forward in phase 3 with a cervical pre-cancer treatment; advancing multiple immunotherapy clinical programs; and collaborating with multiple strategic partners. These two executives strengthen our management team and bring to Inovio global pharma industry experience and a track record of helping organizations reach their goals."

About Inovio Pharmaceuticals, Inc.

Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, Regeneron, Genentech, The Wistar Institute, University of Pennsylvania, DARPA, GeneOne Life Science, Plumbline Life Sciences, ApolloBio Corporation, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and Laval University. For more information, visit **www.inovio.com**.

This press release contains certain forward-looking statements relating to our business. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including the availability and timing of data from ongoing clinical trials, uncertainties inherent in the completion of ongoing clinical trials and the initiation of future clinical trials, whether the results of earlier clinical trials will be indicative of the results of future trials, expectations for regulatory approvals, the availability of funding to support continuing research and studies, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that the company and its collaborators hope to develop and other factors discussed in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2016, filed with the U.S. Securities and Exchange Commission (SEC) on March 15, 2017, our Form 10-Q for the quarter ended March 31, 2017, filed with the SEC on May 10, 2017, and other filings that Inovio makes with the SEC from time to time. There can be no assurance that any product candidate in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical trials will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

In addition, the forward-looking statements included in this press release represent Inovio's views as of the date hereof. Inovio anticipates that subsequent events and developments may cause its views to change. However, while Inovio may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing Inovio's views as of any date subsequent to the date of this release.

CONTACTS:
Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, **bhertel@inovio.com**
Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, **jrichardson@inovio.com**

Source: Inovio Pharmaceuticals